GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2303.2

(-1.26%)

Net Income Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual net income in 2023 was 5.89 Billion INR , down -3.39% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly net income in 2024 Q2 was 2.52 Billion INR , up 38.49% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported an annual net income of 6.1 Billion INR in 2022, up 60.38% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported an annual net income of 3.8 Billion INR in 2021, up 6.32% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly net income of 2.52 Billion INR for 2024 Q2, up 38.49% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly net income of 457.2 Million INR for 2023 Q3, down -78.98% from previous quarter.

Annual Net Income Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Net Income of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Net Income	Net Income Growth
2023	5.89 Billion INR	-3.39%
2022	6.1 Billion INR	60.38%
2021	3.8 Billion INR	6.32%
2020	3.58 Billion INR	284.26%
2019	932.04 Million INR	-79.07%
2018	4.45 Billion INR	26.99%
2017	3.5 Billion INR	4.13%
2016	3.36 Billion INR	-10.62%
2015	3.76 Billion INR	-1.13%
2014	3.81 Billion INR	-20.87%
2013	4.81 Billion INR	-14.28%
2012	5.61 Billion INR	31.1%
2011	4.28 Billion INR	-23.54%
2010	5.6 Billion INR	10.38%
2009	5.07 Billion INR	-14.08%
2008	5.91 Billion INR	7.95%
2007	5.47 Billion INR	-0.63%
2006	5.5 Billion INR	8.65%
2005	5.07 Billion INR	50.19%
2004	3.37 Billion INR	0.0%

Year	Net Income	Net Income Growth
2024 Q1	1.82 Billion INR	-6.25%
2024 Q2	2.52 Billion INR	38.49%
2023 Q3	457.2 Million INR	-78.98%
2023 FY	5.89 Billion INR	-3.39%
2023 Q4	1.94 Billion INR	325.37%
2023 Q1	1.32 Billion INR	-0.88%
2023 Q2	2.17 Billion INR	64.47%
2022 FY	6.1 Billion INR	60.38%
2022 Q2	1.93 Billion INR	62.16%
2022 Q1	1.19 Billion INR	318.22%
2022 Q3	1.64 Billion INR	-14.92%
2022 Q4	1.33 Billion INR	-18.92%
2021 Q4	-546.61 Million INR	-136.36%
2021 Q1	1.21 Billion INR	745.1%
2021 FY	3.8 Billion INR	6.32%
2021 Q2	2.04 Billion INR	68.68%
2021 Q3	1.5 Billion INR	-26.39%
2020 Q1	1.1 Billion INR	-19.73%
2020 FY	3.58 Billion INR	284.26%
2020 Q4	143.27 Million INR	-90.85%
2020 Q3	1.56 Billion INR	104.67%
2020 Q2	764.7 Million INR	-31.0%
2019 Q3	-6.61 Billion INR	-231.51%
2019 FY	932.04 Million INR	-79.07%
2019 Q4	1.38 Billion INR	120.88%
2019 Q1	1.13 Billion INR	-22.66%
2019 Q2	5.02 Billion INR	342.8%
2018 Q2	1 Billion INR	19.92%
2018 FY	4.45 Billion INR	26.99%
2018 Q4	1.46 Billion INR	29.16%
2018 Q3	1.13 Billion INR	12.73%
2018 Q1	840.8 Million INR	0.0%
2017 FY	3.5 Billion INR	4.13%
2017 Q1	264.2 Million INR	0.0%
2016 FY	3.36 Billion INR	-10.62%
2015 FY	3.76 Billion INR	-1.13%
2014 FY	3.81 Billion INR	-20.87%
2013 FY	4.81 Billion INR	-14.28%
2012 FY	5.61 Billion INR	31.1%
2011 FY	4.28 Billion INR	-23.54%
2010 FY	5.6 Billion INR	10.38%
2009 FY	5.07 Billion INR	-14.08%
2008 FY	5.91 Billion INR	7.95%
2007 FY	5.47 Billion INR	-0.63%
2006 FY	5.5 Billion INR	8.65%
2005 FY	5.07 Billion INR	50.19%
2004 FY	3.37 Billion INR	0.0%

Peer Net Income Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Net Income	Net Income Difference
Abbott India Limited	12.01 Billion INR	50.887%
Cipla Limited	41.21 Billion INR	85.686%
Gland Pharma Limited	7.72 Billion INR	23.626%
Kopran Limited	509.56 Million INR	-1057.783%
Marksans Pharma Limited	3.13 Billion INR	-88.065%
NGL Fine-Chem Limited	413.16 Million INR	-1327.9%
Pfizer Limited	5.51 Billion INR	-7.007%
Sanofi India Limited	6.02 Billion INR	2.146%
SMS Pharmaceuticals Limited	498.26 Million INR	-1084.042%
TTK Healthcare Limited	628.41 Million INR	-838.802%